Related references
Note: Only part of the references are listed.Anticancer or carcinogenic? The role of estrogen receptor beta in breast cancer progression
Kang Shen et al.
PHARMACOLOGY & THERAPEUTICS (2023)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Discovery of Thieno[2,3-e]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability
Zhengyu Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer
Xiangping Deng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
David J. Hosfield et al.
ELIFE (2022)
Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer
Jessica Caciolla et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Epigenetic mechanisms in breast cancer therapy and resistance
Liliana Garcia-Martinez et al.
NATURE COMMUNICATIONS (2021)
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER plus Breast Cancer
Jun Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Overcoming Endocrine Resistance in Breast Cancer
Ariella B. Hanker et al.
CANCER CELL (2020)
Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors
Jessica Caciolla et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer
Ming He et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds
Ewgenij Proschak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
European cancer mortality predictions for the year 2019 with focus on breast cancer
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2019)
Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)
Yuanyuan Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Junting Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Jane Guan et al.
CELL (2019)
The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
Irene De Santo et al.
CANCERS (2019)
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ER alpha and ER beta Activity
Niamh M. O'Boyle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Overcoming endocrine resistance in hormone receptor-positive breast cancer
A. AlFakeeh et al.
CURRENT ONCOLOGY (2018)
Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors
Jamie N. Mills et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Hitisha K. Patel et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer
Wentao Nin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
John A. Katzenellenbogen et al.
NATURE REVIEWS CANCER (2018)
Full antagonism of the estrogen receptor without a prototypical ligand side chain
Sathish Srinivasan et al.
NATURE CHEMICAL BIOLOGY (2017)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator
Jiawang Liu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer
Rui Xiong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα plus Breast Cancer
Heather E. Burks et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
Patrick M. Kelly et al.
MOLECULES (2017)
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors
Wei Lv et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator
Takuji Shoda et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Endocrine treatment in breast cancer: Cure, resistance and beyond
Konstantinos Tryfonidis et al.
CANCER TREATMENT REVIEWS (2016)
Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective
Debashis Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A retrospective study and an in vitro study
Lizhi Zhang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
The changing role of ER in endocrine resistance
Agostina Nardone et al.
BREAST (2015)
Reciprocal Regulation of ERα and ERβ Stability and Activity by Diptoindonesin G
Zibo Zhao et al.
CHEMISTRY & BIOLOGY (2015)
Design and Synthesis of Norendoxifen Analogues with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities
Wei Lv et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer
Chu Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Chris De Savi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
Donald P. McDonnell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health
Mark P. Thomas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer
Rinath Jeselsohn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator
Takuji Shoda et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
β-Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand
Niamh M. O'Boyle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
Xiaoyong Fu et al.
BREAST CANCER RESEARCH (2014)
High-Throughput Screening Assays for Estrogen Receptor by Using Coumestrol, a Natural Fluorescence Compound
Caihua Wang et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity
Berkley E. Gryder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Synthesis of Mixed (E,Z)-, (E)-, and (Z)-Norendoxifen with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities
Wei Lv et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: Addressing the Core Issue in the Design of Estrogen Receptor Ligands
John A. Katzenellenbogen
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators
Bryan M. Wittmann et al.
CANCER RESEARCH (2007)
Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: Estrogen antagonists of unusual structure
HB Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Designed multiple ligands. An emerging drug discovery paradigm
R Morphy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model
D Jelovac et al.
CANCER RESEARCH (2005)
Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents
U Sharma et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents
VC Jordan
JOURNAL OF MEDICINAL CHEMISTRY (2003)
A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells
K Mitra et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2002)
Share Paper
